NutraLife BioSciences, Inc. (NLBS) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NutraLife BioSciences, Inc. (NLBS), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 38/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026NutraLife BioSciences, Inc. (NLBS) Sağlık ve Boru Hattı Genel Bakışı
NutraLife BioSciences, Inc. focuses on the development, manufacture, and distribution of nutraceutical, dietary, wellness, and CBD products. Operating in the specialty and generic drug manufacturing sector, the company offers a diverse product line, including CBD-infused and traditional wellness items, sold through multiple channels, including online and retail partnerships.
Yatırım Tezi
NutraLife BioSciences, Inc. presents a speculative investment opportunity within the nutraceutical and CBD market. The company's small size and OTC listing introduce significant risk, highlighted by a negative profit margin of -930.0% and a volatile beta of -15.21. Growth hinges on successful expansion of its product lines and distribution networks, particularly in the competitive CBD market. Investors should closely monitor revenue growth, cost management, and regulatory developments affecting the CBD industry. The company's ability to achieve profitability and navigate the OTC market's challenges will be critical for long-term viability. The absence of a dividend further emphasizes the speculative nature of this investment.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- NutraLife BioSciences operates with a small team of 12 employees, indicating a lean operational structure.
- The company's gross margin stands at 13.3%, reflecting the profitability of its product sales after accounting for the cost of goods sold.
- The company's profit margin is -930.0%, indicating significant losses relative to its revenue.
- NutraLife BioSciences has a beta of -15.21, suggesting an inverse correlation to the market and high volatility.
- The company does not offer a dividend, indicating that it is reinvesting earnings back into the business.
Rakipler & Benzerleri
Güçlü Yönler
- Diverse product line including nutraceutical, dietary, wellness, and CBD products.
- Multiple distribution channels including online, retail, and private label.
- Established manufacturing capabilities.
- Focus on emerging wellness market trends.
Zayıflıklar
- Negative profit margin indicates financial instability.
- Small company size with limited resources.
- OTC listing implies higher risk and lower liquidity.
- Dependence on evolving regulatory environment for CBD products.
Katalizörler
- Upcoming: Potential regulatory changes in the CBD market could create new opportunities or challenges.
- Ongoing: Expansion of product lines and entry into new markets.
- Ongoing: Strategic partnerships with retailers and distributors.
- Upcoming: Release of new clinical studies supporting the efficacy of its products.
- Ongoing: Increased consumer awareness and demand for wellness products.
Riskler
- Potential: Intense competition in the CBD and nutraceutical markets.
- Potential: Changing regulatory landscape for CBD products.
- Ongoing: Negative profit margin indicates financial instability.
- Potential: Product liability claims.
- Ongoing: Dependence on evolving consumer preferences.
Büyüme Fırsatları
- Expansion of CBD Product Lines: The growing market for CBD products presents a significant opportunity for NutraLife BioSciences. By introducing new CBD-infused products, such as edibles, beverages, and specialized formulations, the company can attract a wider customer base. The global CBD market is projected to reach billions of dollars in the coming years, offering substantial revenue potential if NutraLife can effectively innovate and market its offerings. Timeline: Ongoing.
- Strategic Partnerships with Retailers: Collaborating with major retail chains and online marketplaces can significantly expand NutraLife BioSciences' distribution network. Securing shelf space in established stores and online platforms provides access to a larger audience and enhances brand visibility. This strategy can drive sales volume and establish a stronger market presence. The timeline for securing such partnerships typically ranges from several months to a year. Market size: National and international retail market.
- Development of Private Label Products: Offering private label manufacturing services to other companies can generate a stable revenue stream for NutraLife BioSciences. By leveraging its manufacturing capabilities, the company can produce custom formulations and branded products for other businesses, capitalizing on the growing demand for private label wellness products. Timeline: Within the next 1-2 years.
- Geographic Expansion into New Markets: Expanding into new geographic markets, both domestically and internationally, can unlock significant growth opportunities. By targeting regions with high consumer demand for wellness products and favorable regulatory environments, NutraLife BioSciences can diversify its revenue streams and reduce reliance on its existing markets. Market size: Global wellness and nutraceutical market. Timeline: 2-3 years.
- Investment in Online Marketing and E-commerce: Enhancing its online presence through targeted marketing campaigns and improvements to its e-commerce platform can drive direct-to-consumer sales. By optimizing its website for search engines, utilizing social media marketing, and implementing email marketing strategies, NutraLife BioSciences can attract new customers and increase online revenue. Market size: Global e-commerce market. Timeline: Ongoing.
Fırsatlar
- Expansion into new geographic markets.
- Development of innovative CBD-infused products.
- Strategic partnerships with major retailers.
- Growth in the overall wellness and nutraceutical market.
Tehditler
- Intense competition in the CBD and nutraceutical markets.
- Changing regulatory landscape for CBD products.
- Potential for product liability claims.
- Economic downturn impacting consumer spending on wellness products.
Rekabet Avantajları
- Proprietary formulations for nutraceutical and CBD products.
- Established manufacturing capabilities.
- Distribution network through online and retail channels.
- Brand recognition in the wellness market.
NLBS Hakkında
NutraLife BioSciences, Inc., established in 2010 and based in Coconut Creek, Florida, operates in the nutraceutical, dietary, wellness, and CBD product space. Originally incorporated as NutraFuels, Inc., the company rebranded in March 2019 to NutraLife BioSciences, Inc., signaling a strategic shift towards a broader wellness portfolio. The company develops, manufactures, and distributes a variety of products, including cannabinoid-rich hemp oil derived from industrial hemp, tinctures, topical lotions and oils, face creams, massage oils, nutraceutical sprays with CBD, and pet products. Additionally, NutraLife BioSciences offers skincare and sanitizer products, catering to a diverse consumer base seeking wellness and health solutions. NutraLife BioSciences sells its products through its online platform, nutralifebiosciences.com, and leverages partnerships with private label distributors, online retailers, and traditional retail outlets to expand its market reach. The company's focus on both CBD and non-CBD wellness products positions it within the evolving landscape of consumer health and alternative medicine.
Ne Yaparlar
- Develops nutraceutical products.
- Manufactures dietary supplements.
- Creates wellness products.
- Produces cannabidiol (CBD) products.
- Offers cannabinoid-rich hemp oil.
- Distributes products through online and retail channels.
İş Modeli
- Develops and manufactures nutraceutical, dietary, wellness, and CBD products.
- Sells products directly to consumers through its website.
- Partners with private label distributors.
- Distributes products through online retailers and retail outlets.
Sektör Bağlamı
NutraLife BioSciences operates within the specialty and generic drug manufacturing industry, a segment experiencing growth driven by increasing consumer interest in wellness and alternative medicine. The market for CBD products is expanding but faces regulatory uncertainty and intense competition. Companies like ACCA, ACORQ, CBDHF, CHCR, and DGCRF represent key competitors. Success in this landscape requires effective branding, product differentiation, and navigating the evolving regulatory environment surrounding CBD and nutraceutical products.
Kilit Müşteriler
- Individual consumers seeking nutraceutical and wellness products.
- Private label distributors looking for product manufacturing.
- Online retailers selling health and wellness products.
- Retail outlets offering dietary supplements and CBD products.
Finansallar
Grafik & Bilgi
NutraLife BioSciences, Inc. (NLBS) hisse senedi fiyatı: Price data unavailable
Son Haberler
NLBS için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
NLBS için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
NLBS için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, NLBS'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Edgar Ward
CEO
Edgar Ward serves as the CEO of NutraLife BioSciences, Inc. His background includes experience in managing small teams and guiding the company's strategic direction within the nutraceutical and CBD sectors. Details regarding his prior roles and educational background are not available. He is responsible for overseeing the company's operations, product development, and distribution strategies.
Sicil: Under Edgar Ward's leadership, NutraLife BioSciences has focused on expanding its product offerings and distribution channels. Key milestones include the rebranding from NutraFuels, Inc. to NutraLife BioSciences, Inc. in 2019 and the ongoing development of CBD-infused products. However, the company's financial performance remains a challenge, as evidenced by the negative profit margin.
NLBS OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that NutraLife BioSciences may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater price volatility and risk compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure increases information asymmetry.
- Low liquidity can lead to significant price volatility.
- Higher potential for fraud or manipulation compared to exchange-listed companies.
- OTC Other status indicates the company may not meet minimum financial standards.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capitalization structure and potential dilution.
- Monitor news and press releases for any red flags.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 2010.
- Offers a range of products across multiple categories (nutraceutical, dietary, wellness, CBD).
- Sells products through multiple distribution channels (online, retail, private label).
Yatırımcılar NutraLife BioSciences, Inc. (NLBS) Hakkında Ne Soruyor
NLBS için değerlendirilmesi gereken temel faktörler nelerdir?
NutraLife BioSciences, Inc. (NLBS) şu anda yapay zeka skoru 38/100, düşük puanı gösteriyor. Temel güçlü yan: Diverse product line including nutraceutical, dietary, wellness, and CBD products.. İzlenmesi gereken birincil risk: Potential: Intense competition in the CBD and nutraceutical markets.. Bu bir finansal tavsiye değildir.
NLBS MoonshotScore'u nedir?
NLBS şu anda MoonshotScore'da 38/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
NLBS verileri ne sıklıkla güncellenir?
NLBS fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler NLBS hakkında ne diyor?
NLBS için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
NLBS'a yatırım yapmanın riskleri nelerdir?
NLBS için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Intense competition in the CBD and nutraceutical markets.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
NLBS'ın P/E oranı nedir?
NLBS için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için NLBS'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
NLBS aşırı değerli mi, yoksa düşük değerli mi?
NutraLife BioSciences, Inc. (NLBS)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
NLBS'ın temettü verimi nedir?
NutraLife BioSciences, Inc. (NLBS) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited financial data available for NutraLife BioSciences, Inc. due to its OTC listing.
- Information based on available sources and may not be comprehensive.